China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for ...

HUTCHMED (China) agrees to divest its 45% stake in Shanghai Hutchison Pharma for $608M in cash to a group including Shanghai ...

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

Hutchmed (HCM) announces that the new drug application for the combination of Orpathys and Tagrisso for the treatment of patients with locally ...

(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals ...

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative ...

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...